FdaApplication
BLA 761342
Identifiers
- fda_app_no: BLA761342
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 2023-08-09 |
Revenue by product
TALVEY
| Period | Revenue |
|---|---|
| Q2 2026 | $174.0M |
| Q1 2026 | $152.0M |
| Q4 2025 | $149.0M |
| Q3 2025 | $122.0M |
| Q2 2025 | $106.0M |
| Q1 2025 | $86.0M |
| Q4 2024 | $85.0M |
| Q3 2024 | $75.0M |
| Q2 2024 | $69.0M |
| Q1 2024 | $58.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TALVEY | TALQUETAMAB-TGVS | 40MG/ML | Injection |
| TALVEY | TALQUETAMAB-TGVS | 3MG/1.5ML (2MG/ML) | Injection |
2 products